Journal of Advanced Research-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2179917, encodeId=34d521e9917af, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：23年11月投了一篇，半个月以后，以没有找到我文章中的Figure为由send back，我下载下来看Figure就在里面，我又再投，一个月以后又是以没有找到我文章中的Figure为由send back，他么的没有Figure一天不就能看出来，拖了我至少一个半月，我立马删了投别的杂志了，这种煞笔杂志，大家小心吧，拖个半年都有可能。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a7845329653, createdName=148c7eccm12(暂无昵称), createdTime=Mon Jan 08 10:18:01 CST 2024, time=2024-01-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2194212, encodeId=014c219421201, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物化学 经验分享：很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffe79222552, createdName=ms8000000136394924, createdTime=Wed Mar 20 09:19:38 CST 2024, time=2024-03-20, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=971178, encodeId=f0669e1178fc, content=2021.05.13投，2021.06.01拒。需要提供一式三份的WB原图+需要降重。预计修改后resubmission，祝顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211108/2611f9a6a72540698336de10cefb50fb/943487a4316f4a0b8d6cd512c33f07b2.jpg, createdBy=013e2447836, createdName=Beginner_YoonChul, createdTime=Sat Jun 05 20:58:12 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188370, encodeId=641521883e009, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e838161588, createdName=ms4000000389646164, createdTime=Tue Feb 20 19:28:21 CST 2024, time=2024-02-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183177, encodeId=70fd21831e759, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：医学 经验分享：未投未知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f1811609799, createdName=wuxiao2010, createdTime=Mon Jan 22 13:12:05 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2175781, encodeId=cd0921e578189, content=审稿速度:6.0 偏重的研究方向：肿瘤;代谢;免疫细胞 经验分享：8月13日第一次投，18号技术让改格式，29又投回去。9月13改格式，14号with editor，18号under view。10月18号修回，23号修回去，，直至现在一直under view, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b958746065, createdName=ms1000001648241944, createdTime=Tue Dec 19 11:52:08 CST 2023, time=2023-12-19, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2165947, encodeId=be0b216594e1e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：lipid metabolism 经验分享：格式审查了三遍，提交后送审，审稿差不多一个月，给了三周修稿时间，然后我们延迟了两周，五周后投回去，三天后重新送审，两周左右两个审稿人完成了审稿，目前正在decision in process，不知道会是什么结果。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BqCPu9GVaq3OgIeibDXe6pgqb10Ex1wtyEdx42siawAeWZpd8NS9fcoTheXYZqo87BbvOEuCdxaHTnoiaSjmo1aaA/132, createdBy=30c32289387, createdName=静心大魔女, createdTime=Tue Oct 31 19:05:48 CST 2023, time=2023-10-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2175953, encodeId=94f221e59537e, content=11月23号投稿，然后一直是“有待技术评估”到12月16号让改格式、降重，19号改完返回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/e8b5235f7abb4bcf90f5b2245264c95a-jim6YUjGO9EG.jpg, createdBy=cb276420537, createdName=ms5000000738743687, createdTime=Tue Dec 19 20:18:33 CST 2023, time=2023-12-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115343, encodeId=3d8b2115343c0, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：一直在技术审查。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e508484319, createdName=ms6000001830956975, createdTime=Sun Feb 19 00:25:26 CST 2023, time=2023-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141070, encodeId=569421410e065, content=4月26-5月26技术审查，期间退回两次让改格式，26到编辑手里，5.28送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ed6e5440554, createdName=ms8000001941617337, createdTime=Tue Jun 06 14:41:14 CST 2023, time=2023-06-06, status=1, ipAttribution=江苏省)]

2024-01-08 148c7eccm12(暂无昵称) 来自天津

审稿速度:24.0 | 投稿命中率:5.0
经验分享：23年11月投了一篇，半个月以后，以没有找到我文章中的Figure为由send back，我下载下来看Figure就在里面，我又再投，一个月以后又是以没有找到我文章中的Figure为由send back，他么的没有Figure一天不就能看出来，拖了我至少一个半月，我立马删了投别的杂志了，这种煞笔杂志，大家小心吧，拖个半年都有可能。

116 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2179917, encodeId=34d521e9917af, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：23年11月投了一篇，半个月以后，以没有找到我文章中的Figure为由send back，我下载下来看Figure就在里面，我又再投，一个月以后又是以没有找到我文章中的Figure为由send back，他么的没有Figure一天不就能看出来，拖了我至少一个半月，我立马删了投别的杂志了，这种煞笔杂志，大家小心吧，拖个半年都有可能。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a7845329653, createdName=148c7eccm12(暂无昵称), createdTime=Mon Jan 08 10:18:01 CST 2024, time=2024-01-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2194212, encodeId=014c219421201, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物化学 经验分享：很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffe79222552, createdName=ms8000000136394924, createdTime=Wed Mar 20 09:19:38 CST 2024, time=2024-03-20, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=971178, encodeId=f0669e1178fc, content=2021.05.13投，2021.06.01拒。需要提供一式三份的WB原图+需要降重。预计修改后resubmission，祝顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211108/2611f9a6a72540698336de10cefb50fb/943487a4316f4a0b8d6cd512c33f07b2.jpg, createdBy=013e2447836, createdName=Beginner_YoonChul, createdTime=Sat Jun 05 20:58:12 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188370, encodeId=641521883e009, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e838161588, createdName=ms4000000389646164, createdTime=Tue Feb 20 19:28:21 CST 2024, time=2024-02-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183177, encodeId=70fd21831e759, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：医学 经验分享：未投未知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f1811609799, createdName=wuxiao2010, createdTime=Mon Jan 22 13:12:05 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2175781, encodeId=cd0921e578189, content=审稿速度:6.0 偏重的研究方向：肿瘤;代谢;免疫细胞 经验分享：8月13日第一次投，18号技术让改格式，29又投回去。9月13改格式，14号with editor，18号under view。10月18号修回，23号修回去，，直至现在一直under view, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b958746065, createdName=ms1000001648241944, createdTime=Tue Dec 19 11:52:08 CST 2023, time=2023-12-19, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2165947, encodeId=be0b216594e1e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：lipid metabolism 经验分享：格式审查了三遍，提交后送审，审稿差不多一个月，给了三周修稿时间，然后我们延迟了两周，五周后投回去，三天后重新送审，两周左右两个审稿人完成了审稿，目前正在decision in process，不知道会是什么结果。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BqCPu9GVaq3OgIeibDXe6pgqb10Ex1wtyEdx42siawAeWZpd8NS9fcoTheXYZqo87BbvOEuCdxaHTnoiaSjmo1aaA/132, createdBy=30c32289387, createdName=静心大魔女, createdTime=Tue Oct 31 19:05:48 CST 2023, time=2023-10-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2175953, encodeId=94f221e59537e, content=11月23号投稿，然后一直是“有待技术评估”到12月16号让改格式、降重，19号改完返回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/e8b5235f7abb4bcf90f5b2245264c95a-jim6YUjGO9EG.jpg, createdBy=cb276420537, createdName=ms5000000738743687, createdTime=Tue Dec 19 20:18:33 CST 2023, time=2023-12-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115343, encodeId=3d8b2115343c0, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：一直在技术审查。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e508484319, createdName=ms6000001830956975, createdTime=Sun Feb 19 00:25:26 CST 2023, time=2023-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141070, encodeId=569421410e065, content=4月26-5月26技术审查，期间退回两次让改格式，26到编辑手里，5.28送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ed6e5440554, createdName=ms8000001941617337, createdTime=Tue Jun 06 14:41:14 CST 2023, time=2023-06-06, status=1, ipAttribution=江苏省)]

2024-03-20 ms8000000136394924 来自湖南省

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：药物化学
经验分享：很难

44 0

[GetPortalCommentsPageByObjectIdResponse(id=2179917, encodeId=34d521e9917af, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：23年11月投了一篇，半个月以后，以没有找到我文章中的Figure为由send back，我下载下来看Figure就在里面，我又再投，一个月以后又是以没有找到我文章中的Figure为由send back，他么的没有Figure一天不就能看出来，拖了我至少一个半月，我立马删了投别的杂志了，这种煞笔杂志，大家小心吧，拖个半年都有可能。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a7845329653, createdName=148c7eccm12(暂无昵称), createdTime=Mon Jan 08 10:18:01 CST 2024, time=2024-01-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2194212, encodeId=014c219421201, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物化学 经验分享：很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffe79222552, createdName=ms8000000136394924, createdTime=Wed Mar 20 09:19:38 CST 2024, time=2024-03-20, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=971178, encodeId=f0669e1178fc, content=2021.05.13投，2021.06.01拒。需要提供一式三份的WB原图+需要降重。预计修改后resubmission，祝顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211108/2611f9a6a72540698336de10cefb50fb/943487a4316f4a0b8d6cd512c33f07b2.jpg, createdBy=013e2447836, createdName=Beginner_YoonChul, createdTime=Sat Jun 05 20:58:12 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188370, encodeId=641521883e009, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e838161588, createdName=ms4000000389646164, createdTime=Tue Feb 20 19:28:21 CST 2024, time=2024-02-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183177, encodeId=70fd21831e759, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：医学 经验分享：未投未知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f1811609799, createdName=wuxiao2010, createdTime=Mon Jan 22 13:12:05 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2175781, encodeId=cd0921e578189, content=审稿速度:6.0 偏重的研究方向：肿瘤;代谢;免疫细胞 经验分享：8月13日第一次投，18号技术让改格式，29又投回去。9月13改格式，14号with editor，18号under view。10月18号修回，23号修回去，，直至现在一直under view, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b958746065, createdName=ms1000001648241944, createdTime=Tue Dec 19 11:52:08 CST 2023, time=2023-12-19, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2165947, encodeId=be0b216594e1e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：lipid metabolism 经验分享：格式审查了三遍，提交后送审，审稿差不多一个月，给了三周修稿时间，然后我们延迟了两周，五周后投回去，三天后重新送审，两周左右两个审稿人完成了审稿，目前正在decision in process，不知道会是什么结果。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BqCPu9GVaq3OgIeibDXe6pgqb10Ex1wtyEdx42siawAeWZpd8NS9fcoTheXYZqo87BbvOEuCdxaHTnoiaSjmo1aaA/132, createdBy=30c32289387, createdName=静心大魔女, createdTime=Tue Oct 31 19:05:48 CST 2023, time=2023-10-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2175953, encodeId=94f221e59537e, content=11月23号投稿，然后一直是“有待技术评估”到12月16号让改格式、降重，19号改完返回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/e8b5235f7abb4bcf90f5b2245264c95a-jim6YUjGO9EG.jpg, createdBy=cb276420537, createdName=ms5000000738743687, createdTime=Tue Dec 19 20:18:33 CST 2023, time=2023-12-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115343, encodeId=3d8b2115343c0, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：一直在技术审查。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e508484319, createdName=ms6000001830956975, createdTime=Sun Feb 19 00:25:26 CST 2023, time=2023-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141070, encodeId=569421410e065, content=4月26-5月26技术审查，期间退回两次让改格式，26到编辑手里，5.28送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ed6e5440554, createdName=ms8000001941617337, createdTime=Tue Jun 06 14:41:14 CST 2023, time=2023-06-06, status=1, ipAttribution=江苏省)]

2021-06-05 Beginner_YoonChul

2021.05.13投，2021.06.01拒。需要提供一式三份的WB原图+需要降重。预计修改后resubmission，祝顺利！

171 20

展开20条回复

[GetPortalCommentsPageByObjectIdResponse(id=2179917, encodeId=34d521e9917af, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：23年11月投了一篇，半个月以后，以没有找到我文章中的Figure为由send back，我下载下来看Figure就在里面，我又再投，一个月以后又是以没有找到我文章中的Figure为由send back，他么的没有Figure一天不就能看出来，拖了我至少一个半月，我立马删了投别的杂志了，这种煞笔杂志，大家小心吧，拖个半年都有可能。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a7845329653, createdName=148c7eccm12(暂无昵称), createdTime=Mon Jan 08 10:18:01 CST 2024, time=2024-01-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2194212, encodeId=014c219421201, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物化学 经验分享：很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffe79222552, createdName=ms8000000136394924, createdTime=Wed Mar 20 09:19:38 CST 2024, time=2024-03-20, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=971178, encodeId=f0669e1178fc, content=2021.05.13投，2021.06.01拒。需要提供一式三份的WB原图+需要降重。预计修改后resubmission，祝顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211108/2611f9a6a72540698336de10cefb50fb/943487a4316f4a0b8d6cd512c33f07b2.jpg, createdBy=013e2447836, createdName=Beginner_YoonChul, createdTime=Sat Jun 05 20:58:12 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188370, encodeId=641521883e009, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e838161588, createdName=ms4000000389646164, createdTime=Tue Feb 20 19:28:21 CST 2024, time=2024-02-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183177, encodeId=70fd21831e759, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：医学 经验分享：未投未知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f1811609799, createdName=wuxiao2010, createdTime=Mon Jan 22 13:12:05 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2175781, encodeId=cd0921e578189, content=审稿速度:6.0 偏重的研究方向：肿瘤;代谢;免疫细胞 经验分享：8月13日第一次投，18号技术让改格式，29又投回去。9月13改格式，14号with editor，18号under view。10月18号修回，23号修回去，，直至现在一直under view, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b958746065, createdName=ms1000001648241944, createdTime=Tue Dec 19 11:52:08 CST 2023, time=2023-12-19, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2165947, encodeId=be0b216594e1e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：lipid metabolism 经验分享：格式审查了三遍，提交后送审，审稿差不多一个月，给了三周修稿时间，然后我们延迟了两周，五周后投回去，三天后重新送审，两周左右两个审稿人完成了审稿，目前正在decision in process，不知道会是什么结果。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BqCPu9GVaq3OgIeibDXe6pgqb10Ex1wtyEdx42siawAeWZpd8NS9fcoTheXYZqo87BbvOEuCdxaHTnoiaSjmo1aaA/132, createdBy=30c32289387, createdName=静心大魔女, createdTime=Tue Oct 31 19:05:48 CST 2023, time=2023-10-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2175953, encodeId=94f221e59537e, content=11月23号投稿，然后一直是“有待技术评估”到12月16号让改格式、降重，19号改完返回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/e8b5235f7abb4bcf90f5b2245264c95a-jim6YUjGO9EG.jpg, createdBy=cb276420537, createdName=ms5000000738743687, createdTime=Tue Dec 19 20:18:33 CST 2023, time=2023-12-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115343, encodeId=3d8b2115343c0, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：一直在技术审查。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e508484319, createdName=ms6000001830956975, createdTime=Sun Feb 19 00:25:26 CST 2023, time=2023-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141070, encodeId=569421410e065, content=4月26-5月26技术审查，期间退回两次让改格式，26到编辑手里，5.28送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ed6e5440554, createdName=ms8000001941617337, createdTime=Tue Jun 06 14:41:14 CST 2023, time=2023-06-06, status=1, ipAttribution=江苏省)]

2024-02-20 ms4000000389646164 来自浙江省

无

121 0

[GetPortalCommentsPageByObjectIdResponse(id=2179917, encodeId=34d521e9917af, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：23年11月投了一篇，半个月以后，以没有找到我文章中的Figure为由send back，我下载下来看Figure就在里面，我又再投，一个月以后又是以没有找到我文章中的Figure为由send back，他么的没有Figure一天不就能看出来，拖了我至少一个半月，我立马删了投别的杂志了，这种煞笔杂志，大家小心吧，拖个半年都有可能。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a7845329653, createdName=148c7eccm12(暂无昵称), createdTime=Mon Jan 08 10:18:01 CST 2024, time=2024-01-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2194212, encodeId=014c219421201, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物化学 经验分享：很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffe79222552, createdName=ms8000000136394924, createdTime=Wed Mar 20 09:19:38 CST 2024, time=2024-03-20, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=971178, encodeId=f0669e1178fc, content=2021.05.13投，2021.06.01拒。需要提供一式三份的WB原图+需要降重。预计修改后resubmission，祝顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211108/2611f9a6a72540698336de10cefb50fb/943487a4316f4a0b8d6cd512c33f07b2.jpg, createdBy=013e2447836, createdName=Beginner_YoonChul, createdTime=Sat Jun 05 20:58:12 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188370, encodeId=641521883e009, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e838161588, createdName=ms4000000389646164, createdTime=Tue Feb 20 19:28:21 CST 2024, time=2024-02-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183177, encodeId=70fd21831e759, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：医学 经验分享：未投未知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f1811609799, createdName=wuxiao2010, createdTime=Mon Jan 22 13:12:05 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2175781, encodeId=cd0921e578189, content=审稿速度:6.0 偏重的研究方向：肿瘤;代谢;免疫细胞 经验分享：8月13日第一次投，18号技术让改格式，29又投回去。9月13改格式，14号with editor，18号under view。10月18号修回，23号修回去，，直至现在一直under view, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b958746065, createdName=ms1000001648241944, createdTime=Tue Dec 19 11:52:08 CST 2023, time=2023-12-19, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2165947, encodeId=be0b216594e1e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：lipid metabolism 经验分享：格式审查了三遍，提交后送审，审稿差不多一个月，给了三周修稿时间，然后我们延迟了两周，五周后投回去，三天后重新送审，两周左右两个审稿人完成了审稿，目前正在decision in process，不知道会是什么结果。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BqCPu9GVaq3OgIeibDXe6pgqb10Ex1wtyEdx42siawAeWZpd8NS9fcoTheXYZqo87BbvOEuCdxaHTnoiaSjmo1aaA/132, createdBy=30c32289387, createdName=静心大魔女, createdTime=Tue Oct 31 19:05:48 CST 2023, time=2023-10-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2175953, encodeId=94f221e59537e, content=11月23号投稿，然后一直是“有待技术评估”到12月16号让改格式、降重，19号改完返回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/e8b5235f7abb4bcf90f5b2245264c95a-jim6YUjGO9EG.jpg, createdBy=cb276420537, createdName=ms5000000738743687, createdTime=Tue Dec 19 20:18:33 CST 2023, time=2023-12-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115343, encodeId=3d8b2115343c0, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：一直在技术审查。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e508484319, createdName=ms6000001830956975, createdTime=Sun Feb 19 00:25:26 CST 2023, time=2023-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141070, encodeId=569421410e065, content=4月26-5月26技术审查，期间退回两次让改格式，26到编辑手里，5.28送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ed6e5440554, createdName=ms8000001941617337, createdTime=Tue Jun 06 14:41:14 CST 2023, time=2023-06-06, status=1, ipAttribution=江苏省)]

2024-01-22 wuxiao2010 来自安徽省

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：医学
经验分享：未投未知

121 0

[GetPortalCommentsPageByObjectIdResponse(id=2179917, encodeId=34d521e9917af, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：23年11月投了一篇，半个月以后，以没有找到我文章中的Figure为由send back，我下载下来看Figure就在里面，我又再投，一个月以后又是以没有找到我文章中的Figure为由send back，他么的没有Figure一天不就能看出来，拖了我至少一个半月，我立马删了投别的杂志了，这种煞笔杂志，大家小心吧，拖个半年都有可能。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a7845329653, createdName=148c7eccm12(暂无昵称), createdTime=Mon Jan 08 10:18:01 CST 2024, time=2024-01-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2194212, encodeId=014c219421201, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物化学 经验分享：很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffe79222552, createdName=ms8000000136394924, createdTime=Wed Mar 20 09:19:38 CST 2024, time=2024-03-20, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=971178, encodeId=f0669e1178fc, content=2021.05.13投，2021.06.01拒。需要提供一式三份的WB原图+需要降重。预计修改后resubmission，祝顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211108/2611f9a6a72540698336de10cefb50fb/943487a4316f4a0b8d6cd512c33f07b2.jpg, createdBy=013e2447836, createdName=Beginner_YoonChul, createdTime=Sat Jun 05 20:58:12 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188370, encodeId=641521883e009, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e838161588, createdName=ms4000000389646164, createdTime=Tue Feb 20 19:28:21 CST 2024, time=2024-02-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183177, encodeId=70fd21831e759, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：医学 经验分享：未投未知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f1811609799, createdName=wuxiao2010, createdTime=Mon Jan 22 13:12:05 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2175781, encodeId=cd0921e578189, content=审稿速度:6.0 偏重的研究方向：肿瘤;代谢;免疫细胞 经验分享：8月13日第一次投，18号技术让改格式，29又投回去。9月13改格式，14号with editor，18号under view。10月18号修回，23号修回去，，直至现在一直under view, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b958746065, createdName=ms1000001648241944, createdTime=Tue Dec 19 11:52:08 CST 2023, time=2023-12-19, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2165947, encodeId=be0b216594e1e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：lipid metabolism 经验分享：格式审查了三遍，提交后送审，审稿差不多一个月，给了三周修稿时间，然后我们延迟了两周，五周后投回去，三天后重新送审，两周左右两个审稿人完成了审稿，目前正在decision in process，不知道会是什么结果。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BqCPu9GVaq3OgIeibDXe6pgqb10Ex1wtyEdx42siawAeWZpd8NS9fcoTheXYZqo87BbvOEuCdxaHTnoiaSjmo1aaA/132, createdBy=30c32289387, createdName=静心大魔女, createdTime=Tue Oct 31 19:05:48 CST 2023, time=2023-10-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2175953, encodeId=94f221e59537e, content=11月23号投稿，然后一直是“有待技术评估”到12月16号让改格式、降重，19号改完返回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/e8b5235f7abb4bcf90f5b2245264c95a-jim6YUjGO9EG.jpg, createdBy=cb276420537, createdName=ms5000000738743687, createdTime=Tue Dec 19 20:18:33 CST 2023, time=2023-12-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115343, encodeId=3d8b2115343c0, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：一直在技术审查。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e508484319, createdName=ms6000001830956975, createdTime=Sun Feb 19 00:25:26 CST 2023, time=2023-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141070, encodeId=569421410e065, content=4月26-5月26技术审查，期间退回两次让改格式，26到编辑手里，5.28送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ed6e5440554, createdName=ms8000001941617337, createdTime=Tue Jun 06 14:41:14 CST 2023, time=2023-06-06, status=1, ipAttribution=江苏省)]

2023-12-19 ms1000001648241944 来自贵州省

审稿速度:6.0
偏重的研究方向：肿瘤;代谢;免疫细胞
经验分享：8月13日第一次投，18号技术让改格式，29又投回去。9月13改格式，14号with editor，18号under view。10月18号修回，23号修回去，，直至现在一直under view

89 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2179917, encodeId=34d521e9917af, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：23年11月投了一篇，半个月以后，以没有找到我文章中的Figure为由send back，我下载下来看Figure就在里面，我又再投，一个月以后又是以没有找到我文章中的Figure为由send back，他么的没有Figure一天不就能看出来，拖了我至少一个半月，我立马删了投别的杂志了，这种煞笔杂志，大家小心吧，拖个半年都有可能。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a7845329653, createdName=148c7eccm12(暂无昵称), createdTime=Mon Jan 08 10:18:01 CST 2024, time=2024-01-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2194212, encodeId=014c219421201, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物化学 经验分享：很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffe79222552, createdName=ms8000000136394924, createdTime=Wed Mar 20 09:19:38 CST 2024, time=2024-03-20, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=971178, encodeId=f0669e1178fc, content=2021.05.13投，2021.06.01拒。需要提供一式三份的WB原图+需要降重。预计修改后resubmission，祝顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211108/2611f9a6a72540698336de10cefb50fb/943487a4316f4a0b8d6cd512c33f07b2.jpg, createdBy=013e2447836, createdName=Beginner_YoonChul, createdTime=Sat Jun 05 20:58:12 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188370, encodeId=641521883e009, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e838161588, createdName=ms4000000389646164, createdTime=Tue Feb 20 19:28:21 CST 2024, time=2024-02-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183177, encodeId=70fd21831e759, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：医学 经验分享：未投未知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f1811609799, createdName=wuxiao2010, createdTime=Mon Jan 22 13:12:05 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2175781, encodeId=cd0921e578189, content=审稿速度:6.0 偏重的研究方向：肿瘤;代谢;免疫细胞 经验分享：8月13日第一次投，18号技术让改格式，29又投回去。9月13改格式，14号with editor，18号under view。10月18号修回，23号修回去，，直至现在一直under view, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b958746065, createdName=ms1000001648241944, createdTime=Tue Dec 19 11:52:08 CST 2023, time=2023-12-19, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2165947, encodeId=be0b216594e1e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：lipid metabolism 经验分享：格式审查了三遍，提交后送审，审稿差不多一个月，给了三周修稿时间，然后我们延迟了两周，五周后投回去，三天后重新送审，两周左右两个审稿人完成了审稿，目前正在decision in process，不知道会是什么结果。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BqCPu9GVaq3OgIeibDXe6pgqb10Ex1wtyEdx42siawAeWZpd8NS9fcoTheXYZqo87BbvOEuCdxaHTnoiaSjmo1aaA/132, createdBy=30c32289387, createdName=静心大魔女, createdTime=Tue Oct 31 19:05:48 CST 2023, time=2023-10-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2175953, encodeId=94f221e59537e, content=11月23号投稿，然后一直是“有待技术评估”到12月16号让改格式、降重，19号改完返回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/e8b5235f7abb4bcf90f5b2245264c95a-jim6YUjGO9EG.jpg, createdBy=cb276420537, createdName=ms5000000738743687, createdTime=Tue Dec 19 20:18:33 CST 2023, time=2023-12-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115343, encodeId=3d8b2115343c0, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：一直在技术审查。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e508484319, createdName=ms6000001830956975, createdTime=Sun Feb 19 00:25:26 CST 2023, time=2023-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141070, encodeId=569421410e065, content=4月26-5月26技术审查，期间退回两次让改格式，26到编辑手里，5.28送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ed6e5440554, createdName=ms8000001941617337, createdTime=Tue Jun 06 14:41:14 CST 2023, time=2023-06-06, status=1, ipAttribution=江苏省)]

2023-10-31 静心大魔女来自北京

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：lipid metabolism
经验分享：格式审查了三遍，提交后送审，审稿差不多一个月，给了三周修稿时间，然后我们延迟了两周，五周后投回去，三天后重新送审，两周左右两个审稿人完成了审稿，目前正在decision in process，不知道会是什么结果。。。

90 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2179917, encodeId=34d521e9917af, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：23年11月投了一篇，半个月以后，以没有找到我文章中的Figure为由send back，我下载下来看Figure就在里面，我又再投，一个月以后又是以没有找到我文章中的Figure为由send back，他么的没有Figure一天不就能看出来，拖了我至少一个半月，我立马删了投别的杂志了，这种煞笔杂志，大家小心吧，拖个半年都有可能。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a7845329653, createdName=148c7eccm12(暂无昵称), createdTime=Mon Jan 08 10:18:01 CST 2024, time=2024-01-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2194212, encodeId=014c219421201, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物化学 经验分享：很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffe79222552, createdName=ms8000000136394924, createdTime=Wed Mar 20 09:19:38 CST 2024, time=2024-03-20, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=971178, encodeId=f0669e1178fc, content=2021.05.13投，2021.06.01拒。需要提供一式三份的WB原图+需要降重。预计修改后resubmission，祝顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211108/2611f9a6a72540698336de10cefb50fb/943487a4316f4a0b8d6cd512c33f07b2.jpg, createdBy=013e2447836, createdName=Beginner_YoonChul, createdTime=Sat Jun 05 20:58:12 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188370, encodeId=641521883e009, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e838161588, createdName=ms4000000389646164, createdTime=Tue Feb 20 19:28:21 CST 2024, time=2024-02-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183177, encodeId=70fd21831e759, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：医学 经验分享：未投未知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f1811609799, createdName=wuxiao2010, createdTime=Mon Jan 22 13:12:05 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2175781, encodeId=cd0921e578189, content=审稿速度:6.0 偏重的研究方向：肿瘤;代谢;免疫细胞 经验分享：8月13日第一次投，18号技术让改格式，29又投回去。9月13改格式，14号with editor，18号under view。10月18号修回，23号修回去，，直至现在一直under view, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b958746065, createdName=ms1000001648241944, createdTime=Tue Dec 19 11:52:08 CST 2023, time=2023-12-19, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2165947, encodeId=be0b216594e1e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：lipid metabolism 经验分享：格式审查了三遍，提交后送审，审稿差不多一个月，给了三周修稿时间，然后我们延迟了两周，五周后投回去，三天后重新送审，两周左右两个审稿人完成了审稿，目前正在decision in process，不知道会是什么结果。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BqCPu9GVaq3OgIeibDXe6pgqb10Ex1wtyEdx42siawAeWZpd8NS9fcoTheXYZqo87BbvOEuCdxaHTnoiaSjmo1aaA/132, createdBy=30c32289387, createdName=静心大魔女, createdTime=Tue Oct 31 19:05:48 CST 2023, time=2023-10-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2175953, encodeId=94f221e59537e, content=11月23号投稿，然后一直是“有待技术评估”到12月16号让改格式、降重，19号改完返回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/e8b5235f7abb4bcf90f5b2245264c95a-jim6YUjGO9EG.jpg, createdBy=cb276420537, createdName=ms5000000738743687, createdTime=Tue Dec 19 20:18:33 CST 2023, time=2023-12-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115343, encodeId=3d8b2115343c0, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：一直在技术审查。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e508484319, createdName=ms6000001830956975, createdTime=Sun Feb 19 00:25:26 CST 2023, time=2023-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141070, encodeId=569421410e065, content=4月26-5月26技术审查，期间退回两次让改格式，26到编辑手里，5.28送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ed6e5440554, createdName=ms8000001941617337, createdTime=Tue Jun 06 14:41:14 CST 2023, time=2023-06-06, status=1, ipAttribution=江苏省)]

2023-12-19 ms5000000738743687 来自江苏省

11月23号投稿，然后一直是“有待技术评估”到12月16号让改格式、降重，19号改完返回

88 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2179917, encodeId=34d521e9917af, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：23年11月投了一篇，半个月以后，以没有找到我文章中的Figure为由send back，我下载下来看Figure就在里面，我又再投，一个月以后又是以没有找到我文章中的Figure为由send back，他么的没有Figure一天不就能看出来，拖了我至少一个半月，我立马删了投别的杂志了，这种煞笔杂志，大家小心吧，拖个半年都有可能。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a7845329653, createdName=148c7eccm12(暂无昵称), createdTime=Mon Jan 08 10:18:01 CST 2024, time=2024-01-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2194212, encodeId=014c219421201, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物化学 经验分享：很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffe79222552, createdName=ms8000000136394924, createdTime=Wed Mar 20 09:19:38 CST 2024, time=2024-03-20, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=971178, encodeId=f0669e1178fc, content=2021.05.13投，2021.06.01拒。需要提供一式三份的WB原图+需要降重。预计修改后resubmission，祝顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211108/2611f9a6a72540698336de10cefb50fb/943487a4316f4a0b8d6cd512c33f07b2.jpg, createdBy=013e2447836, createdName=Beginner_YoonChul, createdTime=Sat Jun 05 20:58:12 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188370, encodeId=641521883e009, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e838161588, createdName=ms4000000389646164, createdTime=Tue Feb 20 19:28:21 CST 2024, time=2024-02-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183177, encodeId=70fd21831e759, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：医学 经验分享：未投未知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f1811609799, createdName=wuxiao2010, createdTime=Mon Jan 22 13:12:05 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2175781, encodeId=cd0921e578189, content=审稿速度:6.0 偏重的研究方向：肿瘤;代谢;免疫细胞 经验分享：8月13日第一次投，18号技术让改格式，29又投回去。9月13改格式，14号with editor，18号under view。10月18号修回，23号修回去，，直至现在一直under view, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b958746065, createdName=ms1000001648241944, createdTime=Tue Dec 19 11:52:08 CST 2023, time=2023-12-19, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2165947, encodeId=be0b216594e1e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：lipid metabolism 经验分享：格式审查了三遍，提交后送审，审稿差不多一个月，给了三周修稿时间，然后我们延迟了两周，五周后投回去，三天后重新送审，两周左右两个审稿人完成了审稿，目前正在decision in process，不知道会是什么结果。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BqCPu9GVaq3OgIeibDXe6pgqb10Ex1wtyEdx42siawAeWZpd8NS9fcoTheXYZqo87BbvOEuCdxaHTnoiaSjmo1aaA/132, createdBy=30c32289387, createdName=静心大魔女, createdTime=Tue Oct 31 19:05:48 CST 2023, time=2023-10-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2175953, encodeId=94f221e59537e, content=11月23号投稿，然后一直是“有待技术评估”到12月16号让改格式、降重，19号改完返回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/e8b5235f7abb4bcf90f5b2245264c95a-jim6YUjGO9EG.jpg, createdBy=cb276420537, createdName=ms5000000738743687, createdTime=Tue Dec 19 20:18:33 CST 2023, time=2023-12-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115343, encodeId=3d8b2115343c0, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：一直在技术审查。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e508484319, createdName=ms6000001830956975, createdTime=Sun Feb 19 00:25:26 CST 2023, time=2023-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141070, encodeId=569421410e065, content=4月26-5月26技术审查，期间退回两次让改格式，26到编辑手里，5.28送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ed6e5440554, createdName=ms8000001941617337, createdTime=Tue Jun 06 14:41:14 CST 2023, time=2023-06-06, status=1, ipAttribution=江苏省)]

2023-02-19 ms6000001830956975

审稿速度:3.0 | 投稿命中率:50.0
经验分享：一直在技术审查。

31 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2179917, encodeId=34d521e9917af, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：23年11月投了一篇，半个月以后，以没有找到我文章中的Figure为由send back，我下载下来看Figure就在里面，我又再投，一个月以后又是以没有找到我文章中的Figure为由send back，他么的没有Figure一天不就能看出来，拖了我至少一个半月，我立马删了投别的杂志了，这种煞笔杂志，大家小心吧，拖个半年都有可能。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a7845329653, createdName=148c7eccm12(暂无昵称), createdTime=Mon Jan 08 10:18:01 CST 2024, time=2024-01-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2194212, encodeId=014c219421201, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物化学 经验分享：很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffe79222552, createdName=ms8000000136394924, createdTime=Wed Mar 20 09:19:38 CST 2024, time=2024-03-20, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=971178, encodeId=f0669e1178fc, content=2021.05.13投，2021.06.01拒。需要提供一式三份的WB原图+需要降重。预计修改后resubmission，祝顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211108/2611f9a6a72540698336de10cefb50fb/943487a4316f4a0b8d6cd512c33f07b2.jpg, createdBy=013e2447836, createdName=Beginner_YoonChul, createdTime=Sat Jun 05 20:58:12 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188370, encodeId=641521883e009, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e838161588, createdName=ms4000000389646164, createdTime=Tue Feb 20 19:28:21 CST 2024, time=2024-02-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183177, encodeId=70fd21831e759, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：医学 经验分享：未投未知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f1811609799, createdName=wuxiao2010, createdTime=Mon Jan 22 13:12:05 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2175781, encodeId=cd0921e578189, content=审稿速度:6.0 偏重的研究方向：肿瘤;代谢;免疫细胞 经验分享：8月13日第一次投，18号技术让改格式，29又投回去。9月13改格式，14号with editor，18号under view。10月18号修回，23号修回去，，直至现在一直under view, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b958746065, createdName=ms1000001648241944, createdTime=Tue Dec 19 11:52:08 CST 2023, time=2023-12-19, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2165947, encodeId=be0b216594e1e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：lipid metabolism 经验分享：格式审查了三遍，提交后送审，审稿差不多一个月，给了三周修稿时间，然后我们延迟了两周，五周后投回去，三天后重新送审，两周左右两个审稿人完成了审稿，目前正在decision in process，不知道会是什么结果。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BqCPu9GVaq3OgIeibDXe6pgqb10Ex1wtyEdx42siawAeWZpd8NS9fcoTheXYZqo87BbvOEuCdxaHTnoiaSjmo1aaA/132, createdBy=30c32289387, createdName=静心大魔女, createdTime=Tue Oct 31 19:05:48 CST 2023, time=2023-10-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2175953, encodeId=94f221e59537e, content=11月23号投稿，然后一直是“有待技术评估”到12月16号让改格式、降重，19号改完返回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/e8b5235f7abb4bcf90f5b2245264c95a-jim6YUjGO9EG.jpg, createdBy=cb276420537, createdName=ms5000000738743687, createdTime=Tue Dec 19 20:18:33 CST 2023, time=2023-12-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115343, encodeId=3d8b2115343c0, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：一直在技术审查。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e508484319, createdName=ms6000001830956975, createdTime=Sun Feb 19 00:25:26 CST 2023, time=2023-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141070, encodeId=569421410e065, content=4月26-5月26技术审查，期间退回两次让改格式，26到编辑手里，5.28送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ed6e5440554, createdName=ms8000001941617337, createdTime=Tue Jun 06 14:41:14 CST 2023, time=2023-06-06, status=1, ipAttribution=江苏省)]

2023-06-06 ms8000001941617337 来自江苏省

4月26-5月26技术审查，期间退回两次让改格式，26到编辑手里，5.28送审

48 6

展开6条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务